Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Influence of Blood Brain Barrier Permeability on CSF-To-Serum Ratios of Neurobiomarkers in People With HIV.

Journal of neurochemistry·2026
Same author

The Clinical Presentations of Patients With COVID-19 in the Omicron Era: Missed Opportunities in the Antiviral Treatment of SARS-CoV-2 Infections.

Journal of medical virology·2025
Same author

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.

British journal of clinical pharmacology·2025
Same author

[Diarrhea and HIV infection].

Medecine et maladies infectieuses·2024
Same authorSame journal

[Rational use of antibiotics treatment in acute bronchitis].

Medecine et maladies infectieuses·2024
Same author

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

BMC infectious diseases·2023
Same journal

[Etiology and clinical expression of angina].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

[Detection of human rotaviruses in faeces : comparison of five methods].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
See all related articles

Related Experiment Video

Updated: May 21, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

NNRTIs: pharmacological data.

P Dellamonica1, G Di Perri, R Garraffo

  • 1Service d'infectiologie, université de Nice Sophia-Antipolis, CHU de Nice, 06107 Nice, France. dellamonica.p@chu-nice.fr

Medecine Et Maladies Infectieuses
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

Choosing long-term antiretroviral therapy requires evaluating safety, as drugs like efavirenz and nevirapine have different pharmacokinetic profiles. Understanding these differences is crucial for effective HIV treatment and managing residual viremia.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Related Experiment Videos

Last Updated: May 21, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Virology

Background:

  • Long-term safety is a key criterion for antiretroviral therapy (ART) once viral load is controlled.
  • Individual drug safety profiles within therapeutic classes can vary due to pharmacokinetic and pharmacodynamic properties.

Purpose of the Study:

  • To compare the long-term safety of two non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz and nevirapine.
  • To analyze the impact of these NNRTIs on residual viremia, viral reservoirs, and clinical outcomes.

Main Methods:

  • Review of existing data on efavirenz and nevirapine.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Discussion of drug penetration into the central nervous system (CNS) and genital tracts.

Main Results:

  • Pharmacokinetic properties of efavirenz and nevirapine influence residual viremia and viral reservoirs.
  • Clinical consequences and tissue distribution (CNS, genital tracts) differ between the two NNRTIs.
  • Pharmacogenetics may offer insights into individualized treatment responses.

Conclusions:

  • Efavirenz and nevirapine exhibit distinct long-term safety profiles impacting HIV management.
  • Emerging NNRTIs require further assessment for long-term efficacy and safety.
  • Multidisciplinary communication among clinicians, virologists, and pharmacologists is vital for optimal ART selection.